Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls (STTR)
|ClinicalTrials.gov Identifier: NCT01379716|
Recruitment Status : Unknown
Verified December 2010 by Albany Medical College.
Recruitment status was: Recruiting
First Posted : June 23, 2011
Last Update Posted : June 23, 2011
Postherpetic Neuralgia is a painful nerve condition that can occur when nerve fibers are damaged following an outbreak of shingles.
The purpose of this study is to identify and study abnormalities in the nerves and cells in the of patients with postherpetic Neuralgia (PHN) and characterize changes that could be responsible for causing nerve pain. This data will be compared to the tissue of healthy volunteers. Our goal is that this information will lead to the development of better treatment options for people with painful nerve conditions.
|Condition or disease||Intervention/treatment||Phase|
|Postherpetic Neuralgia Healthy Age/Gender Matched Volunteers||Other: skin biopsy||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia (PHN) and Age and Gender-Matched Normal Controls|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||January 2012|
- Other: skin biopsy
Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
- use of genetic data to enhance the search for targeted therapeutic approaches to chronic pain management [ Time Frame: One year ]The skin biopsies will be used to identify the site of expression of selected makers in skin, including nerve fibers and skin substructures in patients with PHN and age and gender-atched normal controls.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01379716
|Contact: Margaret Czerwinski, BSN, RN||(518)firstname.lastname@example.org|
|Contact: Katy Regan, BS||(518)email@example.com|
|United States, New York|
|Albany Medical College||Recruiting|
|Albany, New York, United States, 12208|
|Principal Investigator:||James P. Wymer, MD||Albany Medical College|